Related Experiment Video
Updated: Apr 12, 2026
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease
Lindsey H Malik1, Gagan D Singh1, Ezra A Amsterdam1
1Division of Cardiovascular Medicine, Department of Internal Medicine, University of California Davis Medical Center, Sacramento, California.
Insights
Chagas disease, caused by Trypanosoma cruzi, is a significant parasitic infection in Latin America. Early diagnosis and treatment are crucial for managing cardiac complications and reducing mortality from this widespread disease.
Area of Science:
- Infectious Diseases
- Cardiology
- Parasitology
Background:
- Chagas disease is caused by the protozoan parasite Trypanosoma cruzi, endemic in Latin America.
- Transmission occurs via infected triatomine feces, congenital means, blood transfusions, or oral contact.
- The disease progresses from an acute to a chronic phase, potentially leading to severe cardiac issues.
Purpose of the Study:
- To review the epidemiology, clinical manifestations, diagnosis, and management of Chagas disease.
- To highlight the cardiac implications and mortality associated with chronic Chagas disease.
- To emphasize the need for increased awareness and improved strategies for Chagas disease control.
Main Methods:
- Review of existing literature on Chagas disease.
- Analysis of diagnostic methods, including serologic testing for immunoglobulin G antibodies.
- Summary of current treatment protocols for both the parasitic infection and its cardiac manifestations.
Main Results:
- Chagas disease can cause acute cardiac problems like myocarditis and conduction abnormalities.
- Chronic infection leads to cardiomyopathy in up to 50% of patients, resulting in heart failure and arrhythmias.
- Diagnosis relies on serologic detection of specific antibodies; treatment involves antiparasitics and cardiac management.
Conclusions:
- Chagas disease presents a substantial infectious burden in the Western Hemisphere.
- Effective management requires timely diagnosis, appropriate antiparasitic therapy, and comprehensive cardiac care.
- Increased global awareness is essential to improve patient outcomes and curb disease transmission.
Abstract:
Chagas disease results from infection by the protozoan parasite Trypanosoma cruzi and is endemic in Latin America. T cruzi is most commonly transmitted through the feces of an infected triatomine, but can also be congenital, via contaminated blood transfusion or through direct oral contact. In the acute phase, the disease can cause cardiac derangements such as myocarditis, conduction system abnormalities, and/or pericarditis. If left untreated, the disease advances to the chronic phase. Up to one-half of these patients will develop a cardiomyopathy, which can lead to cardiac failure and/or ventricular arrhythmias, both of which are major causes of mortality. Diagnosis is confirmed by serologic testing for specific immunoglobulin G antibodies. Initial treatment consists of the antiparasitic agents benznidazole and nifurtimox. The treatment of Chagas cardiac disease comprises standard medical therapy for heart failure and amiodarone for ventricular arrhythmias, with consideration for implantable cardioverter-defibrillator. Chagas disease causes the highest infectious burden of any parasitic disease in the Western Hemisphere, and increased awareness of this disease is essential to improve diagnosis, enhance management, and reduce spread.
Related Concept Videos
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:26Heart Failure III: Clinical Manifestations
01:21Rheumatic Heart Disease III: Medical Management
01:25Endocarditis II: Clinical Features of Infective Endocarditis
01:18Endocarditis III: Medical Management
01:30Coronary Artery Disease III: Clinical Manifestations